Increased toxicity when fibrates and statins are administered in combination - A metabolomics approach with rats

Toxicology Letters

Volumn 211, Issue 2, 2012, Pages 187-200

  Strauss, V ^a   Mellert, W ^a   Wiemer, J ^b   Leibold, E ^b   Kamp, H ^a   Walk, T ^b   Looser, R ^b   Prokoudine, A ^b   Fabian, E ^a   Krennrich, G ^a   Herold, M ^b   Van Ravenzwaay, B ^a  

^a BASF SE   (Germany)

^b Metanomics GmbH   (Germany)

Author keywords

Co administration; Fibrates; Metabolome; Rat; Statins

Indexed keywords

AMINO ACID; ATORVASTATIN; CARBOHYDRATE; CATECHOLAMINE; CLOFIBRATE; FATTY ACID; FENOFIBRATE; LIPID; NUCLEIC ACID BASE; PRAVASTATIN; VITAMIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR SYSTEM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; LIPID BLOOD LEVEL; LIVER CELL; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLOME; METABOLOMICS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; RHABDOMYOLYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BLOOD CELL COUNT; BODY WEIGHT; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; EATING; FIBRIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; METABOLOMICS; RATS; TANDEM MASS SPECTROMETRY;

RATTUS;

EID: 84859932922     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.03.798     Document Type: Article

References (39)

1. Baldwin J.R., Witiak D.T., Feller D.R. Disposition of clofibrate in the rat. Biochem. Pharmacol. 1980, 29:3143-3154.
2. Barter P.J., Rye K.-A. Cardioprotective properties of fibrates. Which fibrate, which patients, what mechanism?. Circulation 2006, 113:1553-1555.
3. Beltowski J., Wojcicka G., Jamroz-Wisniewska A. Adverse effects of statins - mechanism and consequences. Curr. Drug Saf. 2009, 4:209-228.
4. Bessman S.P., Carpenter C.L. The creatine-creatine phosphate energy shuttle. Ann. Rev. Biochem. 1985, 54:831-862.
5. Black A.E., Hayes R.N., Roth B.D., Woo P., Woolf T.F. Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab. Dispos. 1999, 27:916-923.
6. Camerino G.M., Pellegrino M.A., Brocca L., Digennaro C., Camerino D.C., Pierno S., Bottinelli R. Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle. Biochem. Pharmacol. 2011, 81:1054-1064.
7. Dora K.A., Rattigan S., Colquhoun E.Q., Clark M.G. Aerobic muscle contraction impaired by serotonin-mediated vasoconstriction. J. Appl. Physiol. 1994, 77(1):277-284.
8. Fibrate-Statin Report Focus on Safety Washington, DC: Pharmacy Benefits Management Services and the Medical Advisory Panel September 2004, Veterans Health Administration, Department of Veterans Affairs.
9. Griffin J.L., Bollard M.E. Metabonomics: its potential as a tool in toxicology for safety assessment and data integration. Curr. Drug Metab. 2004, 5:389-398.
10. Jacobson T.A. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat. Rev. Endocrinol. 2009, 5(9):507-518.
11. Jurevics H., Hostettler J., Barrett C., Morell P., Toews A.D. Diurnal and dietary-induced changes in cholesterol synthesis correlate with levels of mRNA for HMG-CoA reductase. J. Lipid Res. 2000, 41:1048-1053.
12. Lau Y.Y., Okochi H., Huang Y., Benet L.Z. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab. Dispos. 2006, 34:1175-1181.
13. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423-1427.
14. Lefer A.M., Scalia R., Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc. Res. 2001, 49:281-287.
15. Lindon J.C., Holmes E., Nicholson J.K. Toxicological applications of magnetic resonance. Prog. Nucl. Magn. Reson. Spectrosc. 2004, 45:109-143.
16. Lindon J.C., Holmes E., Bollard M.E., Stanley E.G., Nicholson J.K. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004, 9:1-31.
17. Looser R., Krotzky A.J., Trethewey R.N. Metabolite profiling with GC-MS and LC-MS - a key tool for contemporary biology. Metabolome Analyses - Strategies for Systems Biology 2005, 103-118. Springer, New York. S. Vaidyanathan, G.G. Harrigan, R. Goodacre (Eds.).
18. Mellert W., Kapp M., Strauss V., Wiemer J., Kamp H., Walk T., Looser R., Prokoudine A., Fabian E., Herold M., van Ravenzwaay B. Nutritional impact on the plasma metabolome of rats. Toxicol. Lett. 2011, 207:173-181.
19. Mukhtar R.Y., Reid J., Reckless J.P. Pitavastatin. Int. J. Clin. Pract. 2005, 59:239-252.
20. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: mechanism and clinical relevance. Clin. Pharmacol. Ther. 2006, 80(6):565-581.
21. Newman J.M., Dora K.A., Rattigan S., Edwards S.J., Colquhoun E.Q., Clark M.G. Norepinephrine and serotonin vasoconstriction in rat hindlimb control different vascular flow routes. Am. J. Physiol. Endocrinol. Metab. 1996, 270(4):E689-E699.
22. Ohta T., Masutomi N., Tsutsui N., Sakairi T., Mitchell M., Milburn M.V., Ryals J.A., Beebe K.D., Guo L. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer344 male rats. Toxicol. Pathol. 2009, 37:521-535.
23. Ostlund R.E. Phyrosterols, cholesterol absorption and healthy diets. Lipids 2007, 42:41-45.
24. Pan W.-J., Gustavson L.E., Achari R., Rieser M.J., Ye X., Gutterman C., Wallin B.A. Lack of clinically significant pharmacokinetic interaction beween fenofibrate and pravastatin in healthy volunteers. J. Clin. Pharmacol. 2000, 40:316-323.
25. Prinz V., Endres M. The acute (cerebro)vascular effects of statins. Anesth. Analg. 2009, 109(2):572-584.
26. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramaniam R., Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 2002, 30(11):1280-1287.
27. Roessner U., Wagner C., Kopka J., Trethewey R.N., Willmitzer L. Technical advance: simultaneous analysis of metabolites in potato tuber by gas chromatography-mass spectrometry. Plant J. 2000, 23(1):131-142.
28. Shepherd J. Mechanism of action of fibrates. Postgrad. Med. J. 1993, 69(Suppl. 1):S34-S41.
29. Shirasaka Y., Suzuki K., Nakanishi T., Tamai I. Intestinal apsorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide. Pharm. Res. 2010, 27:2141-2149.
30. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.-C. Mechanisma of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
31. Strauss V., Wiemer J., Leibold E., Kamp H., Walk T., Mellert W., Looser R., Prokoudine A., Fabian E., Krennrich G., Herold M., van Ravenzwaay B. Influence of strain and sex on the metabolic profile of rats in repeated dose toxicological studies. Toxicol. Lett. 2009, 191:88-95.
32. van Ravenzwaay B., Coelho-Palermo Cunha G., Leibold E., Looser R., Mellert W., Prokoudine A., Walk T., Wiemer J. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol. Lett. 2007, 172:21-28.
33. van Ravenzwaay B., Coelho-Palermo Cunha G., Fabian E., Herold M., Kamp H., Krennrich G., Krotzky A., Leibold E., Looser R., Mellert W., Prokoudine A., Strauss V., Trethewey R., Walk T., Wiemer J. The use of metabolomics in cancer research. An Omics Perspective of Cancer 2010, 141-166. Springer Science+Business Media B.V. W.C.S. Cho (Ed.).
34. Weckwerth W., Morgenthal K. Metabolomics: from patter recognition to biological interpretation. Drug Discovery Today 2005, 10:1551-1558.
35. Weil A., Caldwell J., Strolin-Benedetti M. The metabolism and disposition of fenofibrate in rat, guinea pig, and dog. Drug Metab. Dispos. 1988, 16(2):302-309.
36. Wiezbicki A.S., Mikhailidis D.P., Wray R., Schachter M., Cramb R., Simpson W.G., Byren C.B. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr. Med. Res. Opin. 2003, 19(3):155-168.
37. Wilson I.D., Plumb R., Granger J., Major H., Williams R., Lenz E.M. HPLC-MS-based methods for the study of metabonomics. J. Chromatogr. B 2005, 817:67-76.
38. Yamada H., Yamahara A., Yasuda S., Abe M., Oguri K., Fukushima S., Ikeda-Wada S. Dansyl chloride derivatization of methamphetamine: a method with advantages for screening and analysis of methamphetamine in urine. J Anal. Toxicol. 2002, 26:17-22.
39. Yang L.P.H., Keating G.M. Fenofibric acid in combination therapy in the treatment of mixed dyslipidemia. Am. J. Cardiovasc. Drugs 2009, 9(6):401-409.